Neonatal acellular pertussis vaccination may be a safe alternative to maternal immunization, according to efficacy data presented at IDWeek 2015.
IDWeek 2015: Vaccines
Due to several potential barriers, the rates of completion for the human papillomavirus (HPV) vaccine series are lower among HIV-positive patients and men at Denver Health, a large urban public healthcare system, researchers reported at IDWeek 2015.
Attenuated live rotavirus vaccine (RV5) appears to be safe and immunogenic among HIV-positive and HIV-exposed but uninfected (HEU) infants, according to findings from the randomized, double-blind, Phase 2 IMPAACT P1072 study reported at IDWeek 2015.
Quadrivalent live attenuated influenza vaccine (LAIV4) was effective against B strains vs. no vaccine or trivalent/quadrivalent inactivated influenza vaccines (IIV3/4), but not against A/H3N2 strains during the 2014-2015 influenza season in children, results of a multicenter study presented at IDWeek 2015 have found.
The bivalent rLP2086 meningococcal serogroup B vaccine coadministered with MCV4 and Tdap met noninferiority immunogenicity criteria without a clinically significant increase in reactogenicity, a study representing the first report of concomitant adolescent vaccination of all three vaccines concluded at IDWeek 2015.
Vaccines in tablet form delivered to a mucosal site provide both practical and immunologic advantages, Wendy Peters, PhD, from Vaxart Inc., South San Francisco, CA, explained at IDWeek 2015.
The investigational inactivated herpes zoster subunit vaccine, HZ/su, was more reactogenic than placebo in the Phase 3 ZOE-50 (Zoster Efficacy Study in Adults Aged 50 Years and Over) study, found authors of a sub-cohort analysis of injection-site and systemic reactions.
Researchers reported a “low to moderate” influenza vaccine effectiveness for preventing influenza admissions during the northern hemisphere’s 2013/2014 flu season.
Want to read more?
Please login or register first to view this content.